Karyopharm and BMS to Evaluate CC- 92480 Mezigdomide + Selinexor in Patients with R/R Multiple Myeloma November 7, 2023
First Patient dosed in Landmark STAR-LLD Lenalidomide Ph 1b Trial in Multiple Myeloma October 11, 2023
FAILED TRIAL: Ph 3 CANOVA Study of Venetoclax in Patients with RRMM failed to meet primary endpoint of PFS improvement October 3, 2023
Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent CRR reported October 3, 2023
FDA Approves TALVEY™ (talquetamab-tgvs) for the Treatment of Patients with Heavily Pretreated Multiple Myeloma August 16, 2023
FDA clears IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma August 2, 2023
Positive CHMP Opinions for TALVEY (talquetamab) and TECVAYLI (teclistamab) for the Treatment of Patients with R/R Multiple Myeloma July 27, 2023
Positive final KappaMab Ph2b study results in in kappa-type R/R multiple myeloma patients announced July 12, 2023
K36 Therapeutics Announces $70M Series B Financing to Fund Clinical Proof of Concept of KTX-1001 for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14) July 5, 2023
FDA gives go-ahead to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma June 21, 2023
Supplemental BLA submitted to FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with R/R Multiple Myeloma June 14, 2023
First-Ever Results from Dual Bispecific Combination Study Showing 96% ORR in Patients with R/R Multiple Myeloma June 6, 2023
Longer-Term Talquetamab Follow-Up Data Showing ORR of More Than 70% in Heavily Pretreated Patients with Multiple Myeloma presented June 6, 2023
Type II variation application to EMA submitted for a new indication for CARVYKTI in adult patients with relapsed and lenalidomide-refractory multiple myeloma May 31, 2023
